Form 4: Immunocore Holdings Director Acquires Share Options

Kristine Peterson, a director at Immunocore Holdings plc, acquired share options exercisable for 26,198 ordinary shares.

Summary

• On May 15, 2025, Kristine Peterson, a director of Immunocore Holdings plc, was granted share options.
• The options allow her to purchase 26,198 ordinary shares at an exercise price of $29.06 per share.
• The options vest on the earlier of May 15, 2026, or the day before the next annual general meeting, contingent on continuous service.
• The options expire on May 14, 2035.
• Following the transaction, Peterson directly owns 26,198 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of share options to a director is a common practice and suggests confidence in the company's future performance. There are no negative indicators in the filing.

Positives

• The acquisition of share options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector, to align their interests with those of shareholders.
• The vesting schedule of one year is fairly standard.
• The ten year expiry is also standard.

Stakeholder Impact

• The granting of share options to a director can align their interests with those of shareholders, potentially leading to increased shareholder value.

Key Dates

Keywords

Immunocore Holdings, Director, Share Options, IMCR, Beneficial Ownership, Form 4